Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
Healthcare
$4.48 -1.44%
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
52W Low $2.52High $13.67
Volume 1.05M
Average 0.94M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$169.83M
FY 2025 · Annual
Net Income
-$161.31M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.66M | 7.03M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.71M | 2.13M | 0 |
| Gross Profit | 5.66M | 7.03M | (1.71M) | (2.13M) | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 25.85M | 28.4M | 48.22M | 112.47M | 133.72M |
| Selling, General & Admin | 6.15M | 8.01M | 12.48M | 30.13M | 36.11M |
| Operating Expenses | 32M | 36.41M | 60.7M | 140.47M | 169.83M |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| EBITDA | (25.76M) | (27.78M) | (58.47M) | (125.2M) | (159.02M) |
| EBITDA Margin | -455.5% | -395.4% | — | — | — |
| Operating Income | (26.35M) | (29.38M) | (62.41M) | (142.6M) | (169.83M) |
| Operating Margin | -465.8% | -418.3% | — | — | — |
| Interest Income | 1K | 565K | 2.28M | 15.36M | 9.09M |
| Interest Expense | 3K | 65K | 187K | 142K | 489K |
| Other Income / Expenses | (4K) | 491K | 2.04M | 15.13M | 8.52M |
| Income Before Tax | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Pre-Tax Margin | -465.9% | -411.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Net Margin | -465.9% | -411.3% | — | — | — |
| EPS (Basic) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| EPS (Diluted) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| 25.8M | 25.8M | 673.62M | 38.33M | 44.26M | |
| 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
KYTX Earnings Waterfall · TTM
NASDAQ:KYTX · Revenue to Net Income
Key Ratios
EPS$-3.28
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.2
P/S Ratio0.0
Analysis
$0 of revenue converted into -$156.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.28, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Oct 19, 2026 | |
| 8-K | Current report | Sep 24, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much revenue does KYTX generate?
Kyverna Therapeutics, Inc. (KYTX) reported $0.00 of revenue in fiscal 2025.
Is KYTX profitable?
Kyverna Therapeutics, Inc. (KYTX) reported -$161.31M of net income.
Continue the stock analysis
Jump to another research area for this company.